


Serial Number: 10/607,051
Page 2 of 2

This listing of claims will replace all prior versions, and listings, of claims in the application (note that amendments are highlighted in **bold**):

Listing of Claims:

1. (Currently Amended) A compound represented by the structural formula



formula I

or a pharmaceutically acceptable salt or solvate wherein

X is $-\text{CH}_2-$, $-\text{SO}_2-$, carbonyl, $-\text{CHCH}_3$ or $-\text{C}(\text{CH}_3)_2-$;

Y is $-(\text{CR}^2\text{R}^3)_p\text{C}(\text{O})\text{NH}-$, wherein p is a number from 1 to 3 and when p is more than 1, each (CR^2R^3) can be the same or different;

n is 0, such that no connecting bond exists between the two carbons adjacent to the nitrogen;

r is 1;


Ar is aryl or R^6 -substituted aryl;

R^1 is hydrogen, ~~alkyl, cycloalkyl, aralkyl, heterocyclyl, heteroaralkyl, $\text{C}(\text{O})\text{R}^5$, $\text{C}(\text{O})\text{OR}^5$, $\text{C}(\text{O})\text{NR}^8\text{R}^9$, SO_2R^5 , $\text{SO}_2\text{NR}^8\text{R}^9$, aryl, heteroaryl, CF_3 , alkyl substituted with R^{10} , cycloalkylalkyl, cycloalkylalkyl substituted with R^{10} on the cycloalkyl ring,~~

methyl, ethyl, hydroxyethyl, cyclobutyl, cyclopentyl, cycloheptyl, -propyl, $-\text{SO}_2\text{CH}_3$, $-\text{SO}_2\text{N}(\text{CH}_3)_2$, $-\text{COCH}_3$, $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$, isopropyl, cyclopropylmethyl,


Serial Number: 10/607,051

Page 3 of 3




R^2 and R^3 can be the same or different, each being independently hydrogen or -alkyl; or R^2 and R^3 can be joined together with the carbon to which they are attached to form a 3 to 7-membered ring;

R^4 is aryl, R^7 -substituted aryl, or



R^5 is -alkyl, aryl, aralkyl or heteroaryl;

R^6 is 1 to 3 substituents, each R^6 can be the same or different and each is independently selected from the group consisting of -OH, -alkoxy, -OCF₃, -CN, -alkyl, halogen, -NR⁸R⁹, -C(O)NR⁸R⁹, -NR⁸SO₂R⁵, -SO₂NR⁸R⁹, -SO₂R⁵, -C(O)R⁵, -C(O)OR⁵, -CF₃, -(CR²R³)_p-NR⁸R⁹ where p'' is a number from 1 to 3, -CHO,



R^7 is hydrogen or 1 to 4 substituents, each R^7 can be the same or different and each is independently selected from the group consisting of -OH, -alkoxy, -OCF₃, -CN, halogen, -nitro, -NR⁸R⁹, -NR⁸C(O)R⁵, -C(O)NR⁸R⁹, -NR⁸SO₂R⁵, -SO₂NR⁸R⁹, -SO₂R⁵, -C(O)R⁵, -C(O)OR⁸, -CF₃, -(CR²R³)_p-NR⁸R⁹, -(CR²R³)_p-NR⁸C(O)R⁵ where p'' is a number from 1 to 3, -C(=NH)NR⁸R⁹, -C(=NCN)NR⁸R⁹ and -CHO; or two adjacent R^7 groups can be joined together to form a methylenedioxy or ethylenedioxy group;

R^8 is hydrogen or -alkyl;

R^9 is hydrogen, -alkyl, aryl, substituted aryl, heteroaryl or aralkyl;

and

Serial Number: 10/607,051

Page 4 of 4

R^{10} is $-\text{OH}$, $-\text{alkoxy}$, $-\text{cycloalkyl}$, $-\text{cycloalkylalkyl}$, $-\text{C}(\text{O})\text{NR}^8\text{R}^9$, $-\text{NR}^8\text{R}^9$, $-\text{NR}^8\text{SO}_2\text{R}^5$, $-\text{NR}^8\text{C}(\text{O})\text{R}^5$, $-\text{NR}^8\text{C}(\text{O})\text{OR}^5$, $-\text{NR}^8\text{C}(\text{O})\text{NR}^8\text{R}^9$, $-\text{C}(\text{O})\text{OH}$ or $-\text{C}(\text{O})\text{OR}^5$.

2. (previously presented) The compound of claim 1 wherein

X is $-\text{SO}_2-$;

R^2 and R^3 are hydrogen or alkyl;

and

n is 0.

3. (original) The compound of claim 2 wherein R^2 and R^3 are hydrogen.

4. (previously presented) The compound of claim 1 wherein

X is carbonyl;

R^2 and R^3 are hydrogen or alkyl;

and

n is 0.

5. (original) The compound of claim 4 wherein R^2 and R^3 are hydrogen.

6. (previously presented) The compound of claim 1 wherein

X is $-\text{CH}_2-$;

R^1 is hydrogen, $-\text{alkyl}$, $-\text{cycloalkyl}$, $-\text{cycloalkylalkyl}$, heteroaralkyl, heterocyclyl, $-\text{alkyl}$ substituted with $-\text{cycloalkyl}$, $-\text{alkyl}$ substituted with R^{10} , $-\text{SO}_2\text{NR}^8\text{R}^9$, $-\text{SO}_2\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$ or $-\text{C}(\text{O})\text{OR}^5$;

R^2 and R^3 are hydrogen or alkyl;

n is 0;

and

Ar is aryl or R^6 -substituted aryl.

7. (original) The compound of claim 6 wherein


55187

Serial Number: 10/607,051

Page 5 of 5

R^1 is hydrogen, methyl, ethyl, hydroxyethyl, cyclobutyl, cyclopentyl, cycloheptyl, -propyl, $-\text{SO}_2\text{CH}_3$, $-\text{SO}_2\text{N}(\text{CH}_3)_2$, $-\text{COCH}_3$, $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$, isopropyl,

cyclopropylmethyl, heteroaryl,




R^2 and R^3 are hydrogen;

Ar is R^6 -substituted aryl;

R^6 is 1 to 5 substituents which can be the same or different and each is independently selected from the group consisting of halogen, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{CN}$,

$-\text{CHO}$, $-\text{SO}_2\text{R}^5$, $-\text{C}(\text{O})\text{OR}^6$, $-\text{C}(\text{O})\text{R}^5$, $-\text{C}(\text{O})\text{NR}^8\text{R}^9$ and




and

R^7 is two substituents which can be the same or different and independently selected from halogen, $-\text{CN}$ and $-\text{CF}_3$.


8. (original) The compound of claim 7 wherein R^6 is one substituent.
9. (original) The compound of claim 8 wherein R^6 is at the meta position of Ar.
10. (original) The compound of claim 9 wherein R^6 is $-\text{CN}$.
11. (original) The compound of claim 9 wherein R^6 is $-\text{C}(=\text{NH})\text{NHAr}^1$ or $-\text{C}(=\text{NH})\text{NH}_2$.
12. (original) The compound of claim 10 wherein R^7 is selected from the group consisting of Cl, F and $-\text{CF}_3$.
13. (Currently amended) The compound of claim 4 12 wherein R^1 is hydrogen, methyl, ethyl, hydroxyethyl, cyclobutyl, cyclopentyl, cycloheptyl, -propyl, $-\text{SO}_2\text{CH}_3$, $-\text{SO}_2\text{N}(\text{CH}_3)_2$,

Serial Number: 10/607,051
Page 6 of 6

$-\text{COCH}_3$, $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$, isopropyl, cyclopropylmethyl, **heteroaryl**,



14. (previously presented) The compound of claim 1 wherein
X is $-\text{CH}_2-$;



n is 0;

Ar is R^6 -substituted aryl;

R^1 is alkyl or cyclopropylmethyl;


R^6 is $-\text{CN}$ and is substituted at the meta position of Ar.

and







R^7 is hydrogen or halogen.

15. (original) The compound of claim 14 wherein R^7 is chloride or fluoride.

16. (original) A compound selected from the group consisting of








Serial Number: 10/607,051
Page 7 of 7

8d	
8e	
8f	
7d	
7b	
7c	

55187

Serial Number: 10/607,051






Page 8 of 8

7a	
7e	
8a	
10c	
11c	

55187

Serial Number: 10/607,051







Page 9 of 9

11d	
11e	
11f	
11g	
8g	

55187

Serial Number: 10/607,051







Page 10 of 10

8h	
8i	
11h	
11i	
11b	
11j	

55187

Serial Number: 10/607,051


Page 11 of 11

11a	
12a	
12d	
12e	
12f	
30a	

55187

Serial Number: 10/607,051

Page 12 of 12



or a pharmaceutically acceptable salt or solvate.

17. (original) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in combination with at least one pharmaceutically acceptable carrier.

18. (previously presented) A method of treating obesity, hyperphagia or diabetes comprising administering a therapeutically effective amount of at least one compound of claim 1 to a patient in need of such treatment.

19. (previously presented) A method of treating hyperphagia comprising administering to a patient in need of such treatment a therapeutically effective

Serial Number: 10/607,051
Page 13 of 13

amount of at least one compound of claim 1, or a pharmaceutically acceptable salt or solvate of said compound.

20. (original) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 16 in combination with at least one pharmaceutically acceptable carrier.

21. (previously presented) A method of treating obesity, hyperphagia or diabetes comprising administering a therapeutically effective amount of at least one compound of claim 16 to a patient in need of such treatment.

22. (previously presented) A method of treating hyperphagia comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one compound of claim 16, or a pharmaceutically acceptable salt or solvate of said compound.

Claims 23-30 (canceled)